MedTrace Logo

Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.

NCT07638852 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-06-17

No results posted yet for this study

Summary

This is an open-label, prospective, single-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases.

Conditions

  • TNBC, Triple Negative Breast Cancer
  • Brain Metastasases

Interventions

DRUG

Radiotherapy followed by systemic therapy

Radiotherapy followed by Adebrelimab+Bevacizumab+Cisplatin/Carboplatin

DRUG

Systemic therapy followed by radiotherapy

Adebrelimab+Bevacizumab+Cisplatin/Carboplatin followed by radiotherapy.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07638852 on ClinicalTrials.gov